Just reported
From Stryker's results release of 29 ottobre 2026; its quarterly report has since been filed.
Actual
6,52B USD
+7,6% y/y
-1,0% q/q
Guided
—
No guide given
Actual
1,96 USD
-12% y/y
-41% q/q
Guided
—
No guide given
Actual
1,03B USD
-8,9% y/y
-38% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Le quote di ricavo sono stime per nine months ended 2026-09-30, non cifre tratte da un documento depositato.
Surgical instruments and navigation systems
Powered surgical tools and navigation equipment that help surgeons carry out procedures.
Endoscopy and communications equipment
Cameras and related equipment that let clinicians view inside the body, alongside systems that connect operating-room equipment.
Patient and emergency-care equipment
Hospital beds, patient-handling equipment, emergency monitors and defibrillators, intensive-care disposables, and clinician communication systems.
Minimally invasive vascular devices
Catheters and other devices used in minimally invasive treatment of stroke and venous blood clots.
Brain and cranial surgery products
Products for brain and open-skull surgery, including synthetic bone grafts and products used to treat spinal bone conditions.
Joint and trauma implants and robotic surgery systems
Hip, knee, shoulder, ankle and trauma implants, plus robotic systems and surgical tools used in these operations.
Stryker makes equipment used during operations and in hospital wards, including cameras, surgical instruments, beds, emergency devices and systems that help hospital staff communicate. It also makes minimally invasive devices to treat strokes and blood clots, plus implants and robotic systems used in joint replacement and trauma surgery. It sells mainly to doctors, hospitals and other healthcare facilities, both directly and through distributors.
Costruito dai documenti depositati da Stryker Corp. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
The themes Stryker is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
309,64 USD-0,9%chiusura 13 nov
Dati fino al 30 settembre 2026, dal 10-Q depositato il 30 ottobre 2026
Stryker sells operating-room and hospital-care equipment and minimally invasive stroke and clot-treatment devices to hospitals and clinicians, alongside implants and robots for joint surgery.
Grade A+
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 41 dello storico dei voti di Stryker Corp.. Gli altri 39 risalgono fino a ottobre 2016.
